ANI Pharmaceuticals (NASDAQ:ANIP) announced on April 8, 2026, that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Isosorbide Mononitrate Tablets USP, 10 mg and 20 mg.
The company confirmed the immediate commercial launch of the product, which is the generic equivalent of the reference listed drug (RLD) Monoket®.
Isosorbide mononitrate is a nitrate commonly prescribed for the prevention of angina pectoris (chest pain) caused by coronary artery disease.
The launch represents a strategic addition to ANI’s growing portfolio of established multisource generics.
Management highlighted that the product targets a limited-competition market, a key pillar of ANI’s strategy to focus on niche generics with sustainable margins and high barriers to entry.
ANI Pharmaceuticals has been aggressively expanding its footprint in the specialty and generic sectors through both internal development and strategic acquisitions.
The company’s ability to navigate the FDA approval process for complex or niche formulations has been a significant differentiator in a competitive pharmaceutical landscape.
The introduction of Isosorbide Mononitrate is expected to contribute to the company’s 2026 revenue goals as it leverages its existing distribution network and manufacturing scale.